8-K: Nutra Pharma Changes Auditors Amid Internal Control Weaknesses

Nutra Pharma Corp. announced the resignation of Marcum LLP as its independent auditor and the appointment of Astra Audit & Advisory, citing material weaknesses in internal controls.

Summary

• Marcum LLP resigned as Nutra Pharma Corp.'s independent registered public accounting firm on March 27, 2024.
• Marcum had performed reviews for the quarters ended June 30, 2022, and September 30, 2022, but no periods after September 30, 2022, or prior to June 30, 2022.
• No disagreements on accounting principles, financial statement disclosure, or auditing scope were reported with Marcum.
• Marcum identified several material weaknesses in the company's internal control over financial reporting.
• These weaknesses include a lack of qualified accounting personnel, inadequate segregation of duties, limited checks and balances, insufficient supervision of financial statement preparation, and a lack of independent directors and an independent audit committee.
• Astra Audit & Advisory (AA) was approved by the Board on December 18, 2024, to serve as the new independent registered public accounting firm for the fiscal year ending December 31, 2022.
• The company confirmed no prior consultations with AA on accounting principles or audit opinions that would impair their independence.

Sentiment

Score: 2

Explanation: The disclosure of multiple material weaknesses in internal control over financial reporting, including fundamental issues like lack of qualified personnel and inadequate segregation of duties, indicates severe operational and governance deficiencies. While a new auditor has been appointed, the underlying problems present significant risks to financial integrity and investor confidence, leading to a very negative sentiment.

Positives

• No disagreements with Marcum LLP on accounting principles, financial statement disclosure, or auditing scope or procedure were reported.
• The Board considered prior services by Astra Audit & Advisory and concluded that such services would not adversely affect their independence.

Negatives

• Marcum LLP identified several material weaknesses in the company's internal control over financial reporting.
• These weaknesses include a lack of qualified accounting personnel.
• Inadequate segregation of duties was noted.
• Limited checks and balances in processing cash and other transactions were identified.
• Inadequate supervision, monitoring, and reviewing of financial statement preparation processes were reported.
• A lack of independent directors and an independent audit committee was highlighted.

Risks

• The identified material weaknesses in internal control over financial reporting pose significant risks to the accuracy and reliability of future financial statements.
• Lack of qualified accounting personnel increases the risk of errors and misstatements.
• Inadequate segregation of duties and limited checks and balances heighten the risk of fraud and financial mismanagement.
• Insufficient supervision of financial statement preparation processes could lead to non-compliance with accounting standards and regulatory requirements.
• The absence of independent directors and an independent audit committee raises concerns about corporate governance and oversight, potentially impacting investor confidence.

Future Outlook

The filing does not provide explicit forward-looking statements or guidance regarding future financial performance or operational targets. However, the engagement of a new auditor implies an intent to address past financial reporting issues and ensure compliance for future periods.

Management Comments

• "We have read the statements made by Nutra Pharma Corp. under Item 4.01 of its Form 8-K dated September 3, 2025. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements of Nutra Pharma Corp contained therein." (Marcum LLP)

Industry Context

Changes in independent auditors are common, but a resignation accompanied by identified material weaknesses in internal controls is a significant event. Such disclosures often raise red flags for investors, suggesting potential issues with financial reporting integrity and corporate oversight. The appointment of a new auditor is a necessary step to maintain compliance, but the underlying control deficiencies must be addressed to restore confidence, especially in the highly regulated pharmaceutical and health product industry where transparency and accuracy are paramount.

Comparison to Industry Standards

• The identified material weaknesses, particularly the lack of qualified accounting personnel, inadequate segregation of duties, and limited checks and balances, fall significantly below industry best practices for financial reporting and internal controls.
• Leading companies, such as Johnson & Johnson or Pfizer, maintain robust internal control frameworks, often leveraging advanced ERP systems and dedicated internal audit functions, to ensure accuracy and prevent fraud.
• The absence of independent directors and an independent audit committee is a fundamental governance deficiency, contrasting sharply with the standards of most publicly traded companies, which typically have strong, independent oversight bodies to protect shareholder interests.
• While smaller companies may have fewer resources, these specific weaknesses indicate a systemic failure in basic financial hygiene, which is not comparable to even emerging growth companies that are actively building out their control environments.

Corporate Governance

Stakeholder Impact

• Shareholders: Face increased risk due to unreliable financial reporting, potential for misstatements, and concerns over corporate governance, which could negatively impact share price and long-term value.
• Creditors: May view the company as higher risk due to internal control deficiencies, potentially affecting borrowing terms or access to capital.
• Employees: The lack of qualified accounting personnel suggests potential strain or under-resourcing within the finance department, which could impact morale and operational efficiency.
• Regulatory Authorities: The identified material weaknesses will likely draw scrutiny from the SEC, potentially leading to further inquiries or enforcement actions if not adequately addressed.

Next Steps

• The company is expected to take immediate and comprehensive steps to remediate the identified material weaknesses in its internal control over financial reporting.
• This will likely involve hiring qualified accounting personnel, implementing stronger internal controls and segregation of duties, and establishing an independent audit committee with independent directors.
• The new auditor, Astra Audit & Advisory, will commence its audit for the fiscal year ending December 31, 2022, and will likely focus on the remediation efforts and the integrity of the financial statements.

Key Dates

Recommendation

The disclosure of multiple, fundamental material weaknesses in internal control over financial reporting, including a lack of qualified accounting personnel, inadequate segregation of duties, and a complete absence of independent directors and an independent audit committee, points to severe systemic issues within Nutra Pharma Corp. These deficiencies undermine the reliability of financial statements, expose the company to significant fraud risk, and demonstrate a critical failure in corporate governance. While a new auditor has been appointed, the extent of these weaknesses suggests a prolonged and challenging remediation process, with substantial uncertainty regarding the company's ability to produce accurate financial reports and operate with appropriate oversight. This level of risk warrants a strong sell recommendation, as the company's foundational financial integrity is severely compromised.

Keywords

Nutra Pharma Corp, Marcum LLP, Astra Audit & Advisory, Auditor change, Independent registered public accounting firm, Internal control over financial reporting, Material weaknesses, Corporate governance, SEC filing, 8-K, Financial reporting, Audit committee